Ligand Pharma (LGND) Tops Q2 EPS by 84c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $281.96 +2.46%
Revenue Growth %: -32.2%
Financial Fact:
Weighted average number of common shares - basic: 20.89M
Today's EPS Names:
ALZN, ASPU, USAU, More
Revenue Growth %: -32.2%
Financial Fact:
Weighted average number of common shares - basic: 20.89M
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.42, $0.84 better than the analyst estimate of $0.58. Revenue for the quarter came in at $26.4 million versus the consensus estimate of $24.74 million.
GUIDANCE:
Ligand Pharma sees FY2023 EPS of $4.85-$5.00, versus the consensus of $4.63. Ligand Pharma sees FY2023 revenue of $124-128 million, versus the consensus of $131 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
- Piper Sandler Reiterates Overweight Rating on Block Inc. (XYZ)
- Faraday Future says it regained Nasdaq compliance after equity shortfall
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
